Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: S-78989; VPM 087; VPM087.; XMA-005.2; XMA-0052; XOMA-052

Latest Information Update: 17 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XOMA
  • Developer IRIS; National Eye Institute; North Shore-Long Island Jewish Health System; Novartis; Servier; University of Zurich; XOMA
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Behcet's syndrome; Pyoderma; Uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uveitis
  • Phase II Acne vulgaris; Acute coronary syndromes; Diabetic nephropathies; Giant cell arteritis; Labyrinthitis; Myositis; Osteoarthritis; Schnitzler syndrome; Scleritis
  • Preclinical Colorectal cancer; Renal cell carcinoma
  • Suspended Rheumatoid arthritis
  • No development reported Cancer; Gout; Juvenile rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Discontinued Pyoderma

Most Recent Events

  • 10 Jan 2019 Novartis plans a phase I trial for Colorectal cancer (Metastatic disease, First line therapy, Second line therapy or greater), Oesophageal cancer (Metastatic disease, Second line therapy or greater) and Renal cell carcinoma (Metastatic disease, Second line therapy or greater), in March 2019 (IV) (NCT03798626)
  • 30 Jul 2018 Novartis plans regulatory filings for gevokizumab for Colorectal cancer (First-line therapy) and Renal cell carcinoma (First-line therapy) by 2022
  • 18 Jul 2018 Preclinical trials in Colorectal cancer (First-line therapy) in Switzerland (IV) (Novartis pipeline, July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top